| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 11/16/2005 | EP1594522A1 Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases |
| 11/16/2005 | EP1594513A2 Carbohydrate conjugates to prevent abuse of controlled substances |
| 11/16/2005 | EP1594507A2 Novel antiherpes drug combinations |
| 11/16/2005 | EP1594503A2 Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders |
| 11/16/2005 | EP1594499A1 Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer |
| 11/16/2005 | EP1594491A1 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 11/16/2005 | EP1594485A2 Compositions containing substituted quinolines and substituted diphenyl sulfones and methods of use |
| 11/16/2005 | EP1594473A2 Composition and method for treating age-related disorders |
| 11/16/2005 | EP1594435A2 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| 11/16/2005 | EP1594433A2 Cancer therapy sensitizer |
| 11/16/2005 | EP1594432A2 Short immunomodulatory oligonucleotides |
| 11/16/2005 | EP1594371A1 Compositions containing creatine, creatinine and a methyl xanthine |
| 11/16/2005 | EP1498129B1 Use of adenoviruses mutated in the va genes for cancer treatment |
| 11/16/2005 | EP1487472A4 Stabilization of hypoxia inducible factor (hif) alpha |
| 11/16/2005 | EP1463823A4 Methods of increasing endogenous erythropoietin (epo) |
| 11/16/2005 | EP1345611A4 An antibiotic/analgesic formulation and a method of making this formulation |
| 11/16/2005 | EP1331919A4 Dental composition for hypersensitive teeth |
| 11/16/2005 | EP1299085B1 Improved liposomal camptothecins and uses thereof |
| 11/16/2005 | EP1299084B1 Liposomal antineoplastic drugs and uses thereof |
| 11/16/2005 | EP1294927B1 Screening-method for modulators of methyltransferase-dependent chromosome stability |
| 11/16/2005 | EP1292320B1 Use of extracts from spermatophyte plants with immunomodulating activity |
| 11/16/2005 | EP1263458B1 Lowering serum cholesterol |
| 11/16/2005 | EP1248768B1 Bile acid-substituted phenyl-alkenoylguanidines, method for producing said phenyl-alkenoylguanidines, use thereof as medicaments or diagnostic reagents and medicaments containing the same |
| 11/16/2005 | EP1237543B1 Effervescent histamine h2 antagonist composition |
| 11/16/2005 | EP0979089B1 Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells |
| 11/16/2005 | EP0923378B1 Promotion of wound healing by chemically-modified tetracyclines |
| 11/16/2005 | EP0923370B1 Acetyl choline esterase inhibitors for treating and diagnosing sleep disordered breathing |
| 11/16/2005 | EP0871703B1 Dna encoding glutamate gated chloride channels |
| 11/16/2005 | CN1697830A 嘧啶衍生物 Pyrimidine derivatives |
| 11/16/2005 | CN1697828A New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 11/16/2005 | CN1697661A Methods of treating diabetes using PDE 11A inhibitors |
| 11/16/2005 | CN1697655A Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 11/16/2005 | CN1697654A Use of COx-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections |
| 11/16/2005 | CN1697647A Liquor and method for restraining ache, inflammation and cartilage degradation |
| 11/16/2005 | CN1696301A Process for clavulanic acid production by microbial thallus |
| 11/16/2005 | CN1695738A Compsn. of medication for treating high blood pressure |
| 11/16/2005 | CN1227354C Combination of lactic acid bacteria and its use for prevention and/or treatment of infections and inflammatory conditions |
| 11/16/2005 | CN1227265C Antibodies to CCR5 |
| 11/16/2005 | CN1227258C Use of azalide antibiotic compositions for treating or preventing bacterial or protozoal infection in mammals |
| 11/16/2005 | CN1227033C Method of treating cancer with anti-neurotrophin agents |
| 11/16/2005 | CN1227029C Combination of hypertension converting enzyme inhibitor with a diuretic for treating microcirculation disorders |
| 11/16/2005 | CN1227027C Novel compositions |
| 11/16/2005 | CN1227012C Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 11/16/2005 | CN1227011C Method of treating adenosine depletion |
| 11/16/2005 | CN1227004C Partial fatty acid oxidation inhibitors in treatment of congestive heart failure |
| 11/16/2005 | CN1227002C Active content contained floating form having polyacetic vinylester and polyvinyl pyrrolidone, its preparation and use |
| 11/16/2005 | CN1226996C Anti-adiposis composition based on garlic bulb extracts |
| 11/16/2005 | CN1226982C Oil-in-water emulsion comprising micronised biologically active agent and appropriate emulsified system |
| 11/16/2005 | CN1226981C Medical product package for eradication therapy |
| 11/16/2005 | CN1226973C Vacuum assisted closure system with provision for introduction of agent |
| 11/15/2005 | US6965034 Deoxygenation of epothilone A or B, to form desoxyepothilone used as nontoxic anticarcinogenic agents |
| 11/15/2005 | US6965027 Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
| 11/15/2005 | US6965010 Polypeptideeptide for use in the treatment of cancer, neovascularization defects, retinopathies, arthritis and psoraisis |
| 11/15/2005 | US6964984 Preventing desensitization of receptors |
| 11/15/2005 | US6964978 Dissolving with crystal growth inihibitos; drying |
| 11/15/2005 | US6964971 Oral administering; sustained release |
| 11/15/2005 | US6964968 Respiratory system disorders; cardiovascular disorders; viricides |
| 11/15/2005 | US6964966 Such as 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid for treatment of systemic or topical infections |
| 11/15/2005 | US6964962 A norepinephrine reuptake inhibitor or its salt and a neuroleptic agent |
| 11/15/2005 | US6964959 Use of a methylol-containing compound to treat tumors |
| 11/15/2005 | US6964957 For use in therapy of neurodegenerative diseases and certain cancers |
| 11/15/2005 | US6964953 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| 11/15/2005 | US6964946 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 11/15/2005 | US6964853 Smad6 and uses thereof |
| 11/15/2005 | US6964780 Phosphodiesterase inhibitor; therapy for sexual disorders; sildenafil in polyoxyethylene glycol enteric coating |
| 11/15/2005 | US6964777 An antianxiety agent such as buspirone; a dermal penetration enhancer of given formula such as octyl salicylate; and a volatile liquid such as ethanol |
| 11/15/2005 | US6964776 For therapy of hyperpigmentation and vitiligo |
| 11/15/2005 | US6964761 Administering and depositing interferon in the lungs; for patients are unresponsive to treatment with corticosteroid, cyclophosphamide, and azathioprine; therapeutic dosage pluse immunosuppressant or antiinflammatory agent; drug delivery |
| 11/15/2005 | CA2357833C Treatment of pulmonary hypertension using vasopressin antagonist |
| 11/15/2005 | CA2343148C Quick release pharmaceutical compositions of drug substances |
| 11/10/2005 | WO2005106473A1 Method of screening therapeutic agent for neurodegenerative disease |
| 11/10/2005 | WO2005106039A1 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer |
| 11/10/2005 | WO2005105744A1 Histamine-3 receptor antagonists |
| 11/10/2005 | WO2005105743A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| 11/10/2005 | WO2005105722A1 Crystal comprising (2r)-2-propyloctoic acid and amine |
| 11/10/2005 | WO2005105147A2 Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases |
| 11/10/2005 | WO2005105146A1 Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
| 11/10/2005 | WO2005105145A1 Treatment of infectious diseases |
| 11/10/2005 | WO2005105144A1 LATENT TGF-β ACTIVATION INHIBITOR |
| 11/10/2005 | WO2005105133A2 Methods and compositions for preserving the viability of photoreceptor cells |
| 11/10/2005 | WO2005105120A2 Pharmaceutical combination, active on central nervous system (cns) and set of pharmaceuticals; method of treatment of cns-disorders; means facilitating penetration of the hematoencephalic barrier; pharmaceutical means for endonasal administration |
| 11/10/2005 | WO2005105119A1 5-aminosalicylic acid of slow-released type in magnetic intercalated structure and the preparation method thereof |
| 11/10/2005 | WO2005105116A2 Inhibition of biogenic sulfide production via biocide and metabolic inhibitor combination |
| 11/10/2005 | WO2005105098A2 Preparation for the treatment of cancer |
| 11/10/2005 | WO2005105086A1 Method for reducing gastrointestinal toxicity due to the administration of tegafur |
| 11/10/2005 | WO2005105083A1 Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor |
| 11/10/2005 | WO2005105079A2 Novel imidazoles |
| 11/10/2005 | WO2005105064A2 Modulators of frat-lrp interaction in the treatment of bone-related diseases |
| 11/10/2005 | WO2005089503A3 Cd4-igg2 formulations |
| 11/10/2005 | WO2005082397B1 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| 11/10/2005 | WO2005077385A3 Methods for treating resistant or refractory tumors |
| 11/10/2005 | WO2005076975A3 Complexed polypeptide and adjuvant for improved vaccines |
| 11/10/2005 | WO2005067908A3 Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease |
| 11/10/2005 | WO2005046797A3 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| 11/10/2005 | WO2005023328A3 Methods for intradermal delivery of therapeutics agents |
| 11/10/2005 | WO2005016231A3 Agents and methods for treatment of disease by oligosaccharide targeting agents |
| 11/10/2005 | WO2005002672A3 Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| 11/10/2005 | WO2005000216A3 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| 11/10/2005 | US20050251871 Novel ubiquitin ligases as therapeutic targets |
| 11/10/2005 | US20050251289 Medicament dispenser |